| Richmond, Gary J |
NCT03913195: Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection |
|
|
| Completed | 3 | 46 | US | ibalizumab-uiyk, Trogarzo | TaiMed Biologics Inc., Westat | HIV-1-infection | 10/22 | 10/22 | | |
NCT05275998: TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals |
|
|
| Active, not recruiting | 1/2 | 90 | US | TMB-365/TMB-380, TMB-380 is also known as VRC07-523-LS | TaiMed Biologics Inc. | HIV-1-infection | 11/24 | 11/24 | | |
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab |
|
|
| Recruiting | N/A | 600 | US | No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment | Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research | HIV Infections, Multi-Antiviral Resistance | 06/25 | 12/25 | | |
| Appleby, Vernon F |
NCT03913195: Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection |
|
|
| Completed | 3 | 46 | US | ibalizumab-uiyk, Trogarzo | TaiMed Biologics Inc., Westat | HIV-1-infection | 10/22 | 10/22 | | |
NCT05275998: TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals |
|
|
| Active, not recruiting | 1/2 | 90 | US | TMB-365/TMB-380, TMB-380 is also known as VRC07-523-LS | TaiMed Biologics Inc. | HIV-1-infection | 11/24 | 11/24 | | |
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab |
|
|
| Recruiting | N/A | 600 | US | No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment | Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research | HIV Infections, Multi-Antiviral Resistance | 06/25 | 12/25 | | |
